Casi pharmaceuticals announces first dosing of folotyn® in china

Beijing , feb. 16, 2024 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of folotyn® (pralatrexate injection) to a patient in china. this remarks a pivotal step in casi's commitment to addressing critical medical needs in peripheral t-cell lymphoma in china market.
CASI Ratings Summary
CASI Quant Ranking